1Jayasundar R, Shah T, Vaishya S, et al. In vivo and iovitro MR spectroscopic profile of.centrai neurocytomas [ J ]. J Magn Reson Imaging, 2003,17 (2) :256 - 260.
2Palumbo A, Ciaccone L, Bertola A, et al. Low -dose thalidomide plus dexzmethasone is an effective salvage thetspy for advanced myeloma [ J ]. Heinatologica, 2001,86 ( 4 ) : 399.
2Kumar A, Loughran T, Alsina M, et aI. Mangagement of multiple myeloma: a systematic review and critical appraisal of published studies [J]. Lancet Oncol, 2000, 43 (4): 293-299.
3Sonneveld P, Segeren CM. Changing concepts in MM: from conventional chemotherapy to high-dose treatment [J] .European J Cancer, 2003, 39: 9-18.
4Saunders G, Overview of drug therapy for multiple myeloma [J]. J Oncol Pharm Praet, 2005, 11 (3): 83-100.
5Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients [J]. Blood, 2002, 99 (6):3163-3168.
2Alexanian R,Dimopoulos MA,Delasalle K,et al.Primary dexamet hasone t reatment of multiple myeloma[J].Blood,1992,80(4):887-890.
3Rahjumar SV,Rosiol L,Hussein W,et al.Multicenter,randomized,doubleblind,placebo controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma[J].J Clin Oncol,2008,26(13):2171-2177.
4Barlogie B,Tricot G,Rasmussen E,et al.Total therapy 2 without thalidomide in comparison with total therapy 1:role of intensified induction and posttransplantation consolidation therapies[J].Blood,2006,107(7):2633-2638.
